If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, CYMBALTA should be stopped promptly, and linezoli...
While a 120 mg/day dose was shown to be effective, there is no evidence that doses greater than 60 mg/day confer any additional benefits. Periodically reassess to determine the need for maintenance treatment and the appropriate dosage for such treatment. 2.3 Dosage for Treatment of Generalized ...
Data are lacking to show that doses greater than 60 mg per day confer any additional benefits. Acute episodes generally require several months or more of sustained pharmacological therapy; a periodic review of the need for ongoing maintenance treatment and appropriate dosing is recommended.Use...
To assess the benefits and harms of duloxetine for treating painful neuropathy and different types of chronic pain. We searched The Cochrane Neuromuscular Group Specialized Register (10 March 2009), The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3, 2009), MEDLINE (...
As in most clinical trials aimed at registration of the first drug for a new indication, the benefits of the pioneering trials extend beyond understanding of the drug's safety and efficacy. The duloxetine SUI clinical trials are increasing public awareness of the condition, focusing debate on diag...
Substantial evidence exists for the benefits of CBT in CMP including low back pain, neck pain, temporo-mandibular joint pain, knee osteoarthritis, and fibromyalgia [33]. CBT may also decrease central sensitization [34]. Unfortunately, despite the proven efficacy of CBT, access to this behavioral...
OBJECTIVES: To assess the benefits and harms of duloxetine for treating painful neuropathy and different types of chronic pain. SEARCH STRATEGY: We searched The Cochrane Neuromuscular Group Specialized Register (10 March 2009), The Cochrane Central Register of Controlled Trials (The Cochrane Library Iss...
Duloxetine is FDA pregnancy category C, which means risk to fetal development cannot be ruled out. In animal reproductive studies, duloxetine demonstrated adverse effects on embryo/fetal development. Therefore, the clinician should only prescribe duloxetine if the potential benefits justify the potential ...
Talk to your psychiatrist or healthcare professional about the possible risks and benefits associated with the above medications before starting treatment. It’s up to your psychiatric clinician’s professional judgment whether medication is prescribed.If you are in a life threatening situation – don’...
Duloxetine was approved by the US Food and Drug Administration (FDA) in August 2004 for the treatment of major depressive disorder (MDD). It has been suggested that, due to a more balanced inhibition of 5-HT and NE reuptake, duloxetine can provide enhanced benefits in reliev- ing depression...